Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06982417

InsightRP2 Registry

InsightRP2: a Global Patient Registry for RP2-associated Retinitis Pigmentosa

Status
Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
University of Göttingen · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

InsightRP2 is a secure online patient registry specific to RP2-associated retinitis pigmentosa (RP). It is our goal to further the scientific understanding of this rare disease and to support research in to a gene therapy for RP2-associated RP. We collect medical, genetic and imaging data from people affected by RP2-associated RP and will coduct a natural history study as well as image analysis studies.

Detailed description

There is currently no specific patient registry for RP2-associated retinitis pigmentosa. Due to the rarity of the disease, only a few patients with this disease are seen at various care sites, making clinical care and diagnosis very challenging. In addition, there are numerous knowledge gaps regarding the course of the disease, the disease mechanisms and therapeutic approaches, which poses additional challenges for patient care. Understanding and future treatment of RP2-associated RP is crucial due to its early onset and rapid progression. There is an urgent need for targeted research to develop effective therapies. At the Institute of Human Genetics Göttingen, we have set ourselves the goal of investigating the disease mechanisms of RP2-associated RP and contributing to the long-term development of a therapy for this rare disease. For this purpose, we have set up a patient registry specifically for RP2-associated RP. The registry is fully online, using a secure REDCap-based database hosted at the University Medical Center Göttingen. The medical data collected will enable us to conduct studies on the natural history, mutation distribution and possible genotype-phenotype correlations of this disease. In addition, the collection of medical image data will enable evaluation for the purpose of improving diagnostic processes and supporting therapeutic studies. Last but not least, we aim to form a patient collective who can be offered participation in possible therapy studies at a later date. We will collect retrospective data, however patient's might be recontacted at a later timepoint, which is why we have designated the time perspective as "other" in the description of the study design.

Conditions

Timeline

Start date
2025-05-01
Primary completion
2045-05-01
Completion
2045-05-01
First posted
2025-05-21
Last updated
2025-05-21

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT06982417. Inclusion in this directory is not an endorsement.